Signaling pathways
-
BA6939 ZastaprazanSummary: Zastaprazan (JP-1366) is an inhibitor (WO2018008929). - BA6940 SoraprazanSummary: Soraprazan (BYK61359) is a selective potassium channel competitive (=6.4 nM) inhibitor with an IC of 0.19 μM in the gastric gland.
- BA6941 VerucopeptinSummary: Verucopeptin is a potent (=0.22 μM) inhibitor that reduces the expression of HIF-1 target genes and protein levels of HIF-1α.
- BA6942 5-HydroxylansoprazoleSummary: 5-Hydroxylansoprazole (AG1908) is the active metabolite of Lansoprazole in plasma.
- BA6943 PumaprazoleSummary: A reversible proton pump antagonist.
- BA6944 FR-167356Summary: FR-167356 is an orally potent and selective vesicular ATPase inhibitor with values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and hepatic lysosomal membranes, respectively.
- BA6945 SGLT2-IN-1Summary: SGLT2-IN-1 is an inhibitor of sodium-dependent glucose cotransporter proteins.
- BA6946 MizagliflozinSummary: Mizagliflozin (DSP-3235freebase) is a potent, orally available, selective inhibitor.
- BA6947 LicogliflozinSummary: An inhibitor of sodium-glucose cotransporter protein (and).
- BA6948 KGA-2727Summary: KGA-2727 is a selective, high affinity and orally active inhibitor.